Clinical Trials Browser

INDUSTRY × Interventional × Camurati-Engelmann Syndrome × Clear all

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome

NCT06487624 2026-02-05

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Phase 1 Recruiting

50 enrolled

Lymphoid

Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms

NCT02937272 2025-10-20

A Study of LY3200882 in Participants With Solid Tumors

Phase 1 Active not recruiting

223 enrolled

Camurati-Engelmann Syndrome

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1 Completed

25 enrolled 14 charts

Gynecologic

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Phase 2/3 Terminated

309 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03833661 2023-10-25

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase 2 Completed

159 enrolled 23 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04958434 2023-10-23

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

19 enrolled

Camurati-Engelmann Syndrome, Neoplasms

NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Phase 1/2 Withdrawn

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma